Washington, D.C. 20549

                                      FORM 12b-25

                                 Commission File Number

                              NOTIFICATION OF LATE FILING

(Check One):  [_] Form 10-KSB  [_] Form 11-K  [_] Form 20-F  [X] Form 10-QSB
              [_] Form N-SAR

     For Period Ended:  March 31, 2004

     [_]  Transition Report on Form 10-KSB

     [_]  Transition Report on Form 20-F

     [_]  Transition Report on Form 11-K

     [_]  Transition Report on Form 10-Q

     [_]  Transition Report on Form N-SAR

          For the Transition Period Ended:

     Read attached instruction sheet before preparing form.  Please print
or type.

     Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein.

     If the notification relates to a portion of the filing checked
above, identify the item(s) to which the notification relates:


                                     PART I
                             REGISTRANT INFORMATION

                    Clinical Trials Assistance Corporation
                           Full Name of Registrant

                           Former Name if Applicable

                        31 N. Second Street, Suite 250
         Address of Principal Executive Office (Street and Number)

                              San Jose, CA  95113
                           City, State and Zip Code

                                    PART II
                             RULE 12b-25(b) AND (c)

     If the subject report could not be filed without unreasonable effort
or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate.)

     |    (a)  The reasons described in reasonable detail in Part III of
[X]  |    this form could not be eliminated without unreasonable effort
     |    or expense;
     |    (b)  The subject annual report, semi-annual report, transition
     |    report on Form 10-K, Form  20-F, Form 11-K or Form N-SAR, or
[X]  |    portion thereof  will  be  filed  on or  before  the 15th
     |    calendar day following  the  prescribed  due date; or the subject
     |    quarterly report or transition report on Form 10-Q, or portion
     |    thereof will be filed on or  before  the  fifth  calendar day
     |    following the prescribed due date; and
     |    (c)  The  accountant's statement or other exhibit required by
     |    Rule 12b-25(c) has been attached if applicable.

                                    PART III

     The Registrant's quarterly report on Form 10-QSB cannot be filed within
the prescribed time period due to the accountants requiring additional time
to prepare the financial statements of the Registrant.


                                    PART IV
                               OTHER INFORMATION

(1)  Name and telephone number of person to contact in regard to this

          Kamill Rohny                         (760) 727-8448
          (Name)                             (Area Code) (Telephone Number)

(2)  Have all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that
the registrant was required to file such report(s) been filed?  If the answer
is no, identify report(s).
                                                            [X] Yes  [_] No

(3)  Is it anticipated that any significant change in results of operations
from the corresponding  period for the last fiscal year will be reflected by
the earnings  statements to be included in the subject report or portion
                                                            [_] Yes  [X] No

     If so: attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.

                     Clinical Trials Assistance Corporation
                  (Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.

Date:  May 13, 2004                 /s/ Kamill Rohny
                                   By:  Kamill Rohny

          INSTRUCTION:  The form may be signed by an executive officer of the
     registrant or by any other duly authorized representative.  The name and
     title of the person signing the form shall be typed or printed  beneath
     the signature.  If the  statement is signed on behalf of the  registrant
     by an authorized  representative  (other than an executive officer),
     evidence of the representative's authority to sign on behalf of the
     registrant shall be filed with the form.


     Intentional misstatements or omissions of fact constitute Federal
Criminal Violations (see 18 U.S.C. 1001).